|Bid||107.32 x 1000|
|Ask||107.34 x 1100|
|Day's Range||105.87 - 107.97|
|52 Week Range||78.95 - 108.76|
|Beta (3Y Monthly)||0.84|
|PE Ratio (TTM)||20.26|
|Earnings Date||Oct 21, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||2.12 (2.01%)|
|1y Target Est||108.19|
Quest Diagnostics Recognized for Offering One of the Nation's Best Workforce Health and Well-being Initiatives SECAUCUS, N.J. , Sept. 19, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's ...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Looking at Quest Diagnostics Incorporated's (NYSE:DGX) earnings update in June 2019, analyst consensus outlook appear...
Strategic collaboration aims to improve patient care and reduce costs across thousands of health systems nationwide by delivering insights that empower optimal lab testing SECAUCUS, N.J. and INDIANAPOLIS ...
SECAUCUS, N.J., Sept. 11, 2019 /PRNewswire/ -- One third of U.S. industry sectors experienced year-over-year double-digit increases in workforce drug positivity between 2015 and 2018, according to a new analysis of industry-specific data by Quest Diagnostics (DGX), the world's leading provider of diagnostic information services. The Quest Diagnostics Drug Testing Index™ industry analysis of general U.S. workforce urine drug test results shows year-over-year double-digit increases in workplace drug positivity in six of the 17 sectors reported.
A higher percentage of people nationwide tested positive for a controlled substance in 2018 than in previous years.
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
SECAUCUS, N.J. , Sept. 10, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Manuel O. Méndez has been named Senior ...
Let's talk about the popular Quest Diagnostics Incorporated (NYSE:DGX). The company's shares saw its share price hover...
SECAUCUS, N.J., Aug. 28, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York. Stephen Rusckowski, Chairman, President and CEO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Boston Microfluidics currently offers two tests for lipids and A1C levels, but CEO Brandon Johnson said the current tool could handle up to 13 tests and potentially more.
SECAUCUS, N.J. , Aug. 23, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the ...
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The FMI Large Cap fund doesn’t flee into cash when it sees a bear market on the way. Instead, it buckles down on its value investing philosophy and a concentrated set of stock picks.
The Florida startup has Bay Area investors and is aiming straight at people willing to pay thousands of dollars to beat cancer in the future.
SECAUCUS, N.J. , Aug. 15, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...